Seer, Inc. Receives Unsolicited Acquisition Proposal from CEO Omid Farokhzad, M.D.
Key Highlights for Investors
- Unsolicited Acquisition Proposal: Seer, Inc. (Nasdaq: SEER) announced it has received an unsolicited, non-binding acquisition proposal from its Chair and CEO, Dr. Omid Farokhzad.
- Offer Details: The proposal is to acquire all outstanding shares of Seer’s Class A common stock at \$2.45 per share in cash, plus two separate contingent value rights (CVRs).
- Special Committee Formation: Seer’s Board of Directors will form a Special Committee, comprised solely of independent directors, to evaluate the proposal and explore alternative options.
- No Immediate Shareholder Action Required: Shareholders are not required to take any action at this time.
- Advisors Appointed: The Special Committee will retain independent financial and legal advisors. Perella Weinberg Partners LP will serve as Seer’s financial advisor, and Wilson Sonsini Goodrich & Rosati, Professional Corporation, will serve as legal counsel.
- Forward-Looking Statements: The company cautions that forward-looking statements in this announcement are subject to risks and uncertainties, and there is no assurance that the proposal will lead to a transaction.
Details of the Proposal
On July 2, 2026, Seer, Inc., a leading provider of deep, unbiased proteomic solutions, announced that Dr. Omid Farokhzad, who serves as both Chair and CEO, has submitted an unsolicited, non-binding proposal to acquire all of the company’s Class A common stock. The offer price is \$2.45 per share in cash, accompanied by two contingent value rights. The specifics of these contingent rights have not yet been disclosed, but such rights are typically used in acquisition deals to provide additional value to shareholders if certain milestones are met post-transaction.
The full text of Dr. Farokhzad’s proposal was included in Seer’s Form 8-K filing. Importantly, this proposal has not been accepted, and there is no certainty that any transaction will be consummated.
Board and Special Committee Actions
In response, Seer’s Board of Directors announced the establishment of a Special Committee composed exclusively of independent directors. This committee will rigorously evaluate Dr. Farokhzad’s proposal, as well as other potential strategic alternatives, to determine the best path forward for the company and its shareholders.
The Special Committee will be supported by independent advisors to ensure an impartial review process. Perella Weinberg Partners LP will provide financial advice, and Wilson Sonsini Goodrich & Rosati, Professional Corporation, will act as legal counsel.
Shareholder Impact and Price Sensitivity
This is a material event for Seer shareholders and could have a significant impact on the company’s share price. The \$2.45 per share offer provides a benchmark for valuation, and the market may react based on investors’ views about the likelihood of the proposal being accepted, the potential value of the contingent rights, or the emergence of alternative bids. The involvement of the CEO and Chair in the proposal is particularly notable, as it could raise questions about conflicts of interest or the future direction of the company.
At this stage, shareholders are not required to take any action. The company has emphasized that the Special Committee will independently consider all options and update shareholders in due course.
About Seer, Inc.
Seer, Inc. is recognized for its Proteograph® Product Suite, which uses proprietary engineered nanoparticles, advanced automation, optimized consumables, and analytical software to deliver high-quality proteomic insights. Seer’s products are intended for research use only and are not approved for diagnostic procedures. For more information, investors can visit www.seer.bio.
Contact Information
- Media Contact: Patrick Schmidt, [email protected]
- Investor Contact: Marissa Bych, [email protected]
- External PR: Joele Frank, Wilkinson Brimmer Katcher (Eric Brielmann / Joseph Sala), (212) 355-4449
Forward-Looking Statements Disclaimer
This article includes forward-looking statements, including statements regarding the actions to be taken by the Board and Special Committee and potential strategic outcomes. Actual results may differ materially due to risks and uncertainties, including those described in Seer’s filings with the Securities and Exchange Commission. Seer undertakes no obligation to update such statements, except as required by law. Investors are encouraged to review all company filings and conduct their own due diligence.
